The news: Hims & Hers is expanding its presence in Europe by acquiring Zava, a telehealth company operating in the UK, Germany, France, and Ireland. Terms of the deal have not been disclosed, and Hims expects the deal to be accretive by 2026.

Hims primarily operates in the US, but does work with some licensed physicians in the UK. In 2021, Hims acquired Honest Health, a London-based virtual care company that sells hair loss-related products, for instance.

Zooming out: Hims is dealing with the headwinds of its US weight loss business. The company generated $225 million in weight loss drug sales last year, chiefly from its compounded “copycat” GLP-1 offerings. But the FDA is barring most companies from selling off-brand weight loss drugs since there are no longer shortages of GLP-1s like Ozempic and Zepbound.

Hims is still selling personalized GLP-1 forms that aren't exact copies of their branded counterparts, yet it is losing a big chunk of the broader compounded weight loss drug market due to the recent FDA rulings. Hims recently partnered with Novo Nordisk to offer Wegovy at a discounted price, but even $599/month is too high for many consumers.

The market opportunity: Weight loss drugs are sold at lower prices in Europe than in the US. Hims is likely betting there’s enough demand among international consumers to justify acquiring Zava.

• Hims is adding Zava’s 1.3 million active customers in Europe to its 2.4 million US subscribers.
• Zava already sells Wegovy, Mounjaro, and Saxenda injections on its platform.
• Hims’ marketing prowess could drive awareness of GLP-1s among European consumers. Fewer people in Western Europe (29%) than the global average (37%) are familiar with weight loss drugs, per a May 2025 NielsenIQ survey of consumers in six Western European countries. And 5% have used a weight loss drug in the past, lower than the 8% global average.